Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

pharmafile | February 12, 2019 | News story | Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib 

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 trial, causing shares in the company to fall by as much as 4%.

Gilead’s treatment for Nonalcoholic Steatohepatitis (NASH), a drug called selonsertib, did not meet its primary endpoint in a randomised, double-blind, placebo controlled Phase 3 trial involving 877 patients.

Of the 877 patients, 14.4% of those receiving 18 mg of selonsertib, compared to 12.5% who received 6mg achieved a ≥ 1-stage improvement in fibrosis after 48 weeks of treatment. Meanwhile 12.8% of those who received the placebo achieved similar results.

“While we are disappointed that the STELLAR-4 study did not achieve its primary endpoint, we remain committed to advancing therapies for patients with advanced fibrosis due to NASH, where there is a significant unmet need for effective and well-tolerated treatments,” said Dr John McHutchison, Chief Scientific Officer, Head of Research and Development, Gilead.

Analysts have projected the NASH market to be worth between $20 billion and $35 billion as cases of the fatty liver disease are on the rise.

Louis Goss

Related Content

Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA

Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for …

Inventiva and Echosens collaborate to bring awareness to NASH and encourage screening for at-risk patients

French clinical stage biopharmaceutical company Inventiva has announced a collaboration with US-based high-technology company Echosens …

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech …

Latest content